The ESETT Trial: 2nd Line Medications in Status Epilepticus
Background: Dealing with a patient in status epilepticus, refractory to treatment with benzodiazepines, can be a sphincter tightening ordeal. While most seizure activity responds to appropriately dosed benzodiazipines, some will not respond. The choice of second line medication has been hotly debated (i.e. Levetiracetam, fosphenytoin, and valproate). One of the key aspects of management of … Continue reading The ESETT Trial: 2nd Line Medications in Status Epilepticus
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed